Xortx announces usd $3 million offering

Calgary, alberta, may 19, 2025 (globe newswire) -- xortx therapeutics inc. ("xortx" or the “company”) (nasdaq: xrtx | tsxv: xrtx | frankfurt: anu), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease and gout, announces a non-brokered private placement to raise up to usd $3,000,000 through the issuance of up to 3,409,090 common share units of the company at a price of usd $0.88 per unit (the “offering”). each unit will comprise one common share and one common share purchase warrant (a “warrant”).
XRTX Ratings Summary
XRTX Quant Ranking